摘要:
The invention concerns the use of a compound of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.
摘要:
The invention concerns pharmaceutically useful indoles of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, as well as pharmaceutical compositions containing them. The novel compounds possess inhibitory activity against monocyte chemoattractant protein-1 (MCP-1). The invention further concerns the use of such indoles in the treatment of a disease or condition mediated by MCP-1.
摘要:
The invention concerns the use of a compound of the formula (I) in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.
摘要:
The invention concerns quinazoline derivatives of the formula I wherein X1 is a direct link or a group such as CO, C(R2)2 and CH(OR2); wherein Q1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q2 optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
摘要:
The invention concerns quinazoline derivatives of the formula I ##STR1## wherein X.sup.1 is a direct link or a group such as CO, C(R.sup.2).sub.2 and CH(OR.sup.2);wherein Q.sup.1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents;wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl; andwherein Q.sup.2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q.sup.2 optionally bears up to 3 substituents;or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
摘要:
The invention concerns quinazoline derivatives of formula wherein n is 1, 2 or 3 and each R.sup.2 is independently halogeno; and R.sup.1 is 1-4C)alkoxy-(2-4C)alkylamino; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
摘要:
The invention concerns derivatives of the formula wherein n is 1, 2 or 3 and each R.sup.2 is independently halogeno; and R.sup.1 is amino-(2-4C)alkylamino, (1-4C)alkylamino, (1-4C)alkylamino-(2-4C)alkylamino,di-[(1-4C)alkyl]amino-(2-4C) alkylamino, pyrrolidin-1-yl-(2-4C)alkylamino, piperidino-(2-4C)alkylamino, morpholino-(2-4C)alkylamino, piperazin-1-yl-(2-4C)alkylamino, or 4-(1-4C) alkylpiperazin-1-yl-(2-4C)alkylamino, or pharmaceutically acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
摘要:
The invention concerns 4-anilinoquinazoline derivatives of the formula I ##STR1## wherein m is 1 or 2; each R.sup.1 includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy;n is 1, 2 or 3;each R.sup.2 includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo such as 2-oxo-4-imidazolin-1-yl;or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.